03.11.2016
Biotest AG DE0005227235
DGAP-News: Biotest AG: Biotest AG will offer recombinant factor VIII from 2017
DGAP-News: Biotest AG / Key word(s): Alliance
Biotest AG: Biotest AG will offer recombinant factor VIII from 2017
03.11.2016 / 07:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
/
PRESS RELEASE
Biotest AG will offer recombinant factor VIII from 2017
- Cooperation with Octapharma for German-speaking markets
- Fourth-generation recombinant human factor VIII preparation from a
human cell line
Dreieich, 3 November 2016. Biotest AG will be adding a recombinant factor
VIII preparation to its haemophilia portfolio which will be produced by
using a human cell line from early 2017 on. The new product is indicated
for the treatment and prevention of bleeding episodes in children and
adults with haemophilia A (congenital factor VIII deficiency). It is
intended to be a high-quality alternative for patients who favor a
recombinant product to the recombinant factor VIII preparations available
to date. In studies in previously treated patients, the fourth-generation
recombinant clotting factor has proved to be safe, effective and well
tolerated. Biotest will market the new factor VIII preparation in Germany,
Austria and Switzerland in a cooperation agreement with Octapharma AG,
Lachen, Switzerland.
The factor VIII preparation is produced from a human cell line and thereby
recreates a wild-type preparation like Biotest's Haemoctin(R). Unlike
conventional recombinant factor VIII preparations, which are produced using
hamster cells, the wild-type factor VIII shows natural human structures.
"With a recombinant factor VIII preparation from a human cell line, which
has many of the advantages of a natural plasma clotting factor, we are
continuing our wild-type strategy consistently," states Dr Thomas Becker,
Senior Director Haematology of Biotest AG. "We can now offer an alternative
to patients who together with their doctor deliberately opt for a
recombinant factor VIII preparation."
About recombinant factor VIII
A recombinant clotting factor VIII is produced using biotechnology and is
not obtained from human blood plasma. The blue print (i.e., the gene) for
human factor VIII is introduced into a mammalian cell and inserted into in
the DNA, so it "combines" with the existing genetic material. Hamster
cells, which read the human gene and then produce factor VIII, are
generally used as mammalian cells. Despite the incorporated human gene,
however, a hamster cell is not capable of producing a factor VIII that
corresponds exactly to the human model. There are small structural
differences that can affect tolerability. The recombinant factor VIII that
Biotest will launch on the market is produced in a human cell and thus
comes closest to the natural human model.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus
which are produced by recombinant technologies. Biotest has more than 2,400
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: [email protected]
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: [email protected]
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.de
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover,
Munich, Stuttgart
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
---------------------------------------------------------------------------
03.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [email protected]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
516327 03.11.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Biotest AG ISIN: DE0005227235 können Sie bei EQS abrufen
Gesundheit , 522723 , BIO3 , XETR:BIO3